Jump Financial LLC Takes $1.41 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Jump Financial LLC purchased a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 74,619 shares of the company's stock, valued at approximately $1,406,000. Jump Financial LLC owned 0.10% of Nurix Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NRIX. JPMorgan Chase & Co. lifted its position in shares of Nurix Therapeutics by 85.2% in the third quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company's stock worth $1,531,000 after purchasing an additional 31,352 shares in the last quarter. Barclays PLC increased its stake in Nurix Therapeutics by 77.9% in the 3rd quarter. Barclays PLC now owns 128,344 shares of the company's stock valued at $2,884,000 after buying an additional 56,190 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in Nurix Therapeutics by 42.7% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock worth $14,869,000 after buying an additional 235,971 shares in the last quarter. Norges Bank acquired a new position in shares of Nurix Therapeutics during the 4th quarter worth about $6,006,000. Finally, Raymond James Financial Inc. bought a new position in shares of Nurix Therapeutics in the 4th quarter valued at about $1,026,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Stifel Nicolaus dropped their price objective on Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. Leerink Partners started coverage on Nurix Therapeutics in a research report on Monday, March 17th. They set a "market perform" rating and a $16.00 price target on the stock. Royal Bank of Canada raised their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Leerink Partnrs raised Nurix Therapeutics to a "hold" rating in a report on Monday, March 17th. Finally, HC Wainwright restated a "buy" rating and issued a $36.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $30.44.

Nurix Therapeutics Trading Up 1.3 %

Shares of NRIX traded up $0.15 during mid-day trading on Wednesday, reaching $11.61. 2,507,561 shares of the stock traded hands, compared to its average volume of 895,062. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $29.56. The company has a market cap of $885.10 million, a price-to-earnings ratio of -4.02 and a beta of 2.23. The firm has a fifty day moving average price of $12.93 and a 200 day moving average price of $18.60.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.05. The firm had revenue of $18.45 million for the quarter, compared to analysts' expectations of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same quarter last year, the firm posted ($0.76) EPS. On average, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Houte Hans Van sold 5,825 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now directly owns 33,724 shares in the company, valued at approximately $488,660.76. This represents a 14.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the transaction, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,326 shares of company stock valued at $213,449 in the last quarter. Corporate insiders own 7.40% of the company's stock.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.